-
摘要: 近年来肺癌已成为中国首位恶性肿瘤,其中非小细胞肺癌占80％,由于起病隐匿,大多数患者就诊时已失去手术机会,晚期患者应予以化疗为主的综合治疗,但5年生存率仅12％～15％,晚期患者的中位生存期约8 ～11月.患者经过初次的化疗后病情进展,疗效似乎达到了1个平台,尤其对于初始化疗失败的二线治疗,靶向治疗目前已成为1个研究热点.
-
-
Mrnfrldohn J, Baseiga J. Epidemal growth factor receptor targeting in cancer [J]. Seminars in Oncology, 2006.369. Normanno N, Bianco C, De luca A. Target-based agents against ErbB recepton and their ligands:a novel approach to cancer treatment [J]. Endocrine-Related Cancer, 2003.1. Shepherd F A, Rodrigues Pereira J, Ciuleanu T. Erlotinib in previously treaded non-small-cell lung cancer [J]. New England Journal of Medicine, 2005(2):123. Wheatley-Price P, Ding K, Seymour L. Erlotinib for advanced non-small-cell lung cancer in elderly:an analysis of the Nationa Cancer Institute of Canada Clinical Trails Group Study BR.21 [J]. Journal of Clinical Oncology, 2008, (14):2350. Park K, Lee Js, Wu Y L. Interim safety results from the East/South East(E/SE) Asian subground of the open-label TRUST(Tarceva Lung Cancer Survival Treatment) study of erlotinib for advanced non-small-cell lung cancer [J]. J Thoral Oncol, 2007, (8 suppl 4):S464. 陆舜, 李子明, 成柏君. 厄洛替尼治疗复治的非小细胞肺癌的临床分析 [J]. 中国癌症杂志, 2007, (9):711.doi: 10.3969/j.issn.1007-3639.2007.09.010.
计量
- 文章访问数: 280
- HTML全文浏览量: 21
- PDF下载量: 4
下载:
苏公网安备 32100302010246号
